Abstract

Objective: Surfactant therapy (ST) has significantly reduced mortality and respiratory morbidities among preterm

infants with respiratory distress syndrome (RDS). However, majority of late preterm and term infants with respiratory

distress also suffer from non-RDS lung diseases. In some of these diseases, secondary surfactant deficiency may

develop and ST can be beneficial. In this study we evaluated the indications and early outcomes of ST in late preterm

and term infants.

Material and Methods: We retrospectively evaluated the medical records of 135 late preterm and term infants who

underwent ST between January 2009 and December 2012. The clinical characteristics of the patients, their diagnoses,

number of surfactant application and time of administration, FiO2 requirements before and after ST (1st and 6th

hours),duration of mechanical ventilation, and mortality rate were evaluated.

Results: Among135 late preterm and term patients treated with ST, 78 (57.8%) were given ST due to lung disease other

than RDS and had longer mechanical ventilator duration. In addition, ≥ 2 doses of surfactant requirement, pulmonary

hypertension and mortality rate were found to be higher in these infants. Among patients with RDS, as expected, FiO2

requirement was found to decrease in the 1st and 6th hours after ST (0.60 to 0.50 & 0.37 and p <0.001). Sixteen

percent of newborns with congenital pneumonia required repeated surfactant doses. The FiO2 requirement after ST

was decreased in 42 patients with congenital pneumonia (0.67 to 0.65 & 0.48 and p <0.001). Sixteen patients with

severe meconium aspiration syndrome (median FiO2; 0.98) and 25 patients supporting with high frequency oscillatory

ventilation (HFOV) support did not benefit from ST (p = 0.71 and p = 0.964).

Conclusion: We observed that ST reduced oxygen requirement in the late preterm and term infants with RDS and

congenital pneumonia. However, we found that ST was not beneficial in the infants who applied HFOV due to severe

respiratory insufficiency. We think that prospective studies involving a larger number of patients are needed to determine






treatment options in these patient groups.

Keywords: Meconium aspiration syndrome, Newborn

References

  1. 1. Rubaltelli FF, Dani C, Reali MF, Bertini G, Wiechmann L, Tangucci
  2. M, et al. Acute neonatal respiratory distress in Italy: a one-year
  3. prospective study. Italian Group of Neonatal Pneumology. Acta
  4. Paediatr 1998;87:1261-8.
  5. 2. Horowitz K, Feldman D, Stuart B, Borgida A, Ming Victor Fang
  6. Y, Herson V. Full-term neonatal intenstive care unit admission in
  7. an urban community hospital: the role of respiratory morbidity. J
  8. Matern Fetal Neonatal Med 2011; 24: 1407-10.
  9. 3. Consortium on Safe Labor, Hibbard JU, Wilkins I, Sun L, Gregory
  10. K, Haberman S, Hoffman M, et al. Respiratory morbidity in late
  11. preterm births. JAMA 2010; 304: 419-25.
  12. 4. Soll RF. Prophylactic natural surfactant extract for preventing
  13. morbidity and mortality in preterm infants. Cochrane Database
  14. Syst Rev 2000; 2: CD000511.
  15. 5. Finer NN. Surfactant use for neonatal lung injury: beyond respiratory
  16. distress syndrome. Paediatr Respir Rev 2004; 5 Suppl A: 289-97.
  17. 6. Engle WA; American Academy of Pediatrics Committee on Fetus
  18. and Newborn. Surfactant-replacement therapy for respiratory
  19. distress in the preterm and term neonate. Pediatrics 2008; 121:
  20. 419-32.
  21. 7. D’Angio CT, Sinkin RA, Stevens TP, Landfish NK, Merzbach JL,
  22. Ryan RM, et al. Longitudinal, 15- year follow-up of children born
  23. at less than 29 weeks gestation after introduction of surfactant
  24. therapy into a region: neurologic, cognitive, and educational
  25. outcomes. Pediatrics 2002; 110:1094–102.
  26. 8. Özkan H, Erdeve Ö, Kanmaz Kutman HG, Surfaktan tedavisi. Koç
  27. E, Vural M, editors. Türk Neonatoloji Derneği Respiratuvar Distres
  28. Sendromu ve Sürfaktan Tedavi Rehberi 2018; 9-10.
  29. 9. Deshpande S, Suryawanshi P, Ahya K, Maheshwari R, Gupta S.
  30. Surfactant therapy for early onset pneumonia in late preterm and
  31. term neonates needing mechanical ventilation. J Clin Diagn Res
  32. 2017;11: SC09-SC12.
  33. 10. Fetter WP, Baerts W, Bos AP, van Lingen RA. Surfactant
  34. replacement therapy in neonates with respiratory failure due to
  35. bacterial sepsis. Acta Paediatr 1995; 84: 14-6.

How to cite

1.
Gökçe İK. Surfactant Treatment in Late Preterm and Term Newborns; Indications and Outcomes. Turk J Pediatr Dis [Internet]. 2020 May 29 [cited 2025 Jul. 13];14(3):200-6. Available from: https://turkjpediatrdis.org/article/view/685